Last updated on March 2020

A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx an Antisense Inhibitor of Complement Factor B in Adult Participants With Primary IgA Nephropathy

Brief description of study

The purpose of this study is to evaluate the effectiveness and safety of IONIS-FB-LRx, an antisense inhibitor of complement factor B messenger ribonucleic acid (CFB mRNA), and to evaluate the effect of IONIS-FB-LRx on plasma factor B (FB) levels and serum AH50, CH50 activity in participants with primary immunoglobulin A (IgA) nephropathy.

Detailed Study Description

This is a Phase 2, single arm open-label clinical study in up to 10 participants that will consist of screening period (which may include a titration of maximum dose/maximally tolerated dose of angiotensin converting enzyme (ACE) and/or angiotensin II receptor blocker (ARB)), a 24-week treatment period and a 12-week post-treatment follow-up evaluation period.

Clinical Study Identifier: NCT04014335

Find a site near you

Start Over

IONIS Investigative Site

Parkville, Australia
  Connect »